A groundbreaking study may change how doctors treat glioblastoma, one of the deadliest brain cancers. Researchers Virginia ...

The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis.

A clinical trial of an experimental cell therapy shows promising results for glioblastoma patients, with tumors disappearing ...

A nationwide survey of patients and caregivers has found educational and financial disparities in brain cancer care.

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

According to the American Brain Tumor Association, glioblastomas represent about 14% of all primary brain tumours, with ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Brain cancer specialists emphasize that these long-term survivors are outliers. A generation ago, only the very rare patient with glioblastoma survived this long and the median survival after ...